Coverting Viruses into Therapeutic Tools

On the Road to 50 States road trip, Grant McFadden, Chief Scientific Officer at OncoMyx Therapeutics, talks to Nigel about how the recent pandemic has helped people realize that viruses can be used as agents of good as well as agents of evil.

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

OncoMyx Therapeutics

OncoMyx was founded on breakthrough research demonstrating the myxoma virus is highly immuno-interactive and can selectively infect and kill a broad range of cancer cell types. As a virus that is nonpathogenic to humans, myxoma does not have to overcome pre-existing immunity. With a large genome, myxoma is ideal for multi-arming, creating a precision medicine approach with a unique oncolytic virus that activates the cancer immunity cycle and expands the therapeutic effectiveness of immunotherapies.